New Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs, and Program Leadership Phio ...

Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...

In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum ...

"Canadians wait, on average, more than 65 weeks longer for access to new medicines than Europeans and 90 weeks more than ...

"We are honored to celebrate this year's APhA Foundation Scholarship recipients for their exceptional academic accomplishments and leadership, " said Benjamin Bluml, RPh, APhA Foundation executive ...

As specialty medicines account for an increasing share of the drug pipeline, it makes sense for sponsors to support patients financially, emotionally and logistically.

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional ...

In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision ...

The Texas AG has filed a lawsuit accusing Sanofi of providing kickbacks to doctors, in the form of a free network of nurses ...

Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.